Real-time · AI · Cross-signal

Cingulate just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Cingulate, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

▶

Watch the 2-minute tour · with sound

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024•almost 2 years ago

Contract Type

partnership

Kansas CityBiotechnologyHealthcareHealth CarePharmaceuticalBiopharma

Description

Cingulate Inc. has announced the immediate exercise of certain outstanding warrants, resulting in gross proceeds of approximately $1.86 million. In consideration for the exercise of the warrants for cash, the company will issue new unregistered Series C and D warrants to purchase shares of common stock.

Company Information

Company

Cingulate

Location

Kansas City, Missouri, United States

About

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Cingulate's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months